ClinicalTrials.gg
Status unknownNCT04975204Updated Mar 7, 2022

A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors

A Phase 1 interventional study of TQB3909 Tablets in Advanced Malignant Tumor, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-07.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
126
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3 / 7 activity and caspase 3 / 9 cleavage, and induces apoptosis.

02

Conditions studied

  • Advanced Malignant Tumor
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects volunteered to join the study and signed form (ICF)with good compliance.
  • Age: ≥ 18 years old (when signing ICF); (ECOG) performance status score: 0-1; The expected survival period is more than 3 months.
  • Advanced malignant tumor diagnosed by histology or cytology.
  • Relapse or failure after previous standard treatment, or intolerance to standard treatment, and no other better treatment options.
  • Subject population:a)Dose escalation stage: non-Hodgkin's lymphoma;b) Dose expansion stage: non-Hodgkin's lymphoma, plasmacytoma, acute myeloid leukemia, myelodysplastic syndrome, etc.
  • At least 1 lesion / for efficacy evaluation.
  • The function of main organs are well, and the following examination results are good: routine blood examination, biochemical examination, blood coagulation function examination, and heart color Doppler ultrasound evaluation.
  • Female subjects of childbearing age should agree to use measures (such as intrauterine device, contraceptive or condom) during the study period and within 6 months after the end of the study; The serum pregnancy test iss negative within 7 days before the enrollment and must be non-lactating subjects; Male subjects should agree to avoid childbirth during the study period and within 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Combined disease and History:

    1. There were other malignant tumors in 3 years before the first medication. The following two cases can be included: other malignant tumors treated by single operation have achieved 5-year disease-free survival (DFS) in a row; The cured cervical carcinoma in situ, non melanoma skin cancer and superficial bladder tumor [ta (non-invasive tumor), tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];
    2. The diagnosis was Burkitt lymphoma, lymphoblastic lymphoma / leukemia, etc;
    3. Central nervous system (CNS) invasion was found;
    4. He has received hematopoietic stem cell transplantation in the past;
    5. Autologous hematopoietic stem cell transplantation was performed 3 months before the first administration;
    6. There are many factors influencing oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
    7. Unrelieved toxicity of ≥ circulating tumor cells(CTC) AE 1 due to any previous treatment, excluding alopecia;
    8. Major surgical treatment, open and obvious traumatic injury were performed within 28 days before the study;
    9. There are active or uncontrolled primary hemocytopenia, including autoimmune hemolytic anemia (AIHA), idiopathic thrombocytopenic purpura (ITP), etc;
    10. Arteriovenous thrombotic events occurred within 6 months before the first medication, such as cerebrovascular accident (including , cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism;
    11. Have a history of psychotropic drug abuse and can not quit or have mental disorders;
    12. Subjects with any severe and / or uncontrolled disease included:

      1. Patients with ≥ 2 grade myocardial ischemia 6 months between the first administration or myocardial infarction, arrhythmia (male interval (QTc) > 450ms, female QTc > 470ms) and ≥ 2 grade congestive heart failure ( classification), Cardiac color Doppler ultrasound to evaluate (LVEF)\<50%;
      2. There was active severe infection (≥ CTC AE grade 2 infection);
      3. Fever and neutropenia were found within 1 week before the first medication;
      4. Diabetes was poorly controlled (fasting blood glucose (FBG) > 10mmol/L).
      5. Active hepatitis *;

        * active hepatitis ( reference: hepatitis B surface antigen (HBsAg) positive, and hepatitis B virus(HBV) DNA detection value > 2000 copies /mL or 500 internation unit (IU)/mL; reference: hepatitis C virus(HCV) antibody was positive, and HCV titer detection value exceeded the value);

      6. History of immunodeficiency, including positive or other acquired or congenital immunodeficiency diseases, or organ transplantation;
      7. Patients with epilepsy and need treatment.
  • tumor related symptoms and treatment:

    1. Subjects who have received chemotherapy, radiotherapy within 4 weeks prior to the first dose or received and CAR-T treatment 12 weeks before the first medication, or other anti-tumor treatment within 5 half-life prior to the first dose (the washing and removing period is calculated from the end of the last treatment) ;
    2. Subjects who have previously received BCL-2 inhibitors.
  • Subjects who have received the vaccine within 4 weeks prior to the first dose, or is planning to be vaccinated during the study period.
  • Subjects who have participated in clinical trials of other anti-tumor drugs within 4 weeks before the first dose.
  • According to the judgment of the investigator, subjects with concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects with other reasons which are not suitable for inclusion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    TQB3909 Tablets

    Take 100-1200mg once a day; Oral administration on an empty stomach, 28 days as a cycle.

    Drug: TQB3909 Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity(DLT)

    DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.

    Time frame: up to 18 months

  2. Recommended Phase II Dose (RP2D)

    DLT describes side effects of a drug or other treatment that are serious enough to To evaluate RP2D of TQB3909 tablets in adult patients with advanced solid tumors

    Time frame: up to 18 months

Secondary outcomes

  1. Adverse events (AEs) and serious adverse events (SAEs)

    The incidence and severity of AEs and SAEs, as well as abnormal laboratory test indicators.

    Time frame: up to 18 months

  2. Time to reach maximum(peak )plasma concentration following drug administration (Tmax)

    To characterize the pharmacokinetics of TQB3909 by assessment of time to reach maximum plasma concentration after single and multiple dosing

    Time frame: Within 32 weeks after administration

  3. Maximum (peak) plasma drug concentration (Cmax)

    Cmax is the maximum plasma concentration of TQB3909.

    Time frame: Within 24 hours after administration

  4. Maximum (peak) steady-state plasma drug concentration during a dosage interval (Css-max)

    Css-max is the steady state maximum concentration of TQB3909 .

    Time frame: Within 32 weeks after administration

  5. Area under the plasma concentration-time curve from time zero to time t (AUC0-t)

    To characterize the pharmacokinetics of TQB3909 by assessment of area under the plasma concentration time curve from the first dose to a certain time point.

    Time frame: Within 24 hours after administration

  6. Area under the plasma concentration-time curve from time zero to infinity(AUC0-∞)

    To characterize the pharmacokinetics of TQB3909 by assessment of area under the plasma concentration time curve from the first dose to infinity.

    Time frame: Within 24 hours after administration

  7. Area under the plasma concentration-time curve when reaching steady state (AUCss)

    AUCss is the area under the curve of TQB3909.

    Time frame: Within 32 weeks after administration

  8. Apparent total clearance of the drug from plasma after oral administration (CL/F)

    CL/F is total clearance rate for TQB3909.

    Time frame: Within 24 hours after administration

  9. Elimination half-life (t1/2)

    t1/2 is time it takes for the blood concentration of TQB3909 to drop by half.

    Time frame: Within 24 hours after administration

  10. Mean residence time (MRT)

    MRT describes the average time that TQB3909 remains in the body.

    Time frame: Within 24 hours after administration

  11. Minimum steady-state plasma drug concentration during a dosage interval (Css-min)

    Css-min is the minimum plasma concentration of TQB3909.

    Time frame: Within 32 weeks after administration

  12. Degree of fluctuation(DF)

    DF is the volatility coefficient of TQB3909.

    Time frame: Within 32 weeks after administration

  13. Average steady-state plasma drug concentration during multiple-dose administration (Css-av)

    Css-av is the average of steady-state plasma concentration of TQB3909 .

    Time frame: Within 32 weeks after administration

  14. Apparent volume of distribution after non-intervenous administration (Vd/F)

    Vd/F is the bioavailability corrected apparent distribution volume of TQB3909

    Time frame: Within 24 hours after administration

  15. Progression-free survival (PFS)

    PFS is defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 18 months

  16. Overall response rate (ORR)

    Percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: up to 18 months

  17. Complete response rate(CRR)

    CRR refers to the percentage of patients who enter the clinical disappearance period of the disease after a certain treatment.

    Time frame: up to 18 months

  18. Disease control rate(DCR)

    Percentage of participants achieving CR and PR and stable disease (SD).

    Time frame: up to 18 months

  19. Duration of Response (DOR)

    The period from the participants first achieving CR or PR to disease progression.

    Time frame: up to 18 months

  20. Overall survival (OS)

    OS is defined as the time from the first administration to all-cause death.

    Time frame: up to 18 months

  21. Protein concentration or gene expression level related to BCL-2 signaling pathway

    To evaluate the changes of BCL-2 signaling pathway related to proteins or genes.

    Time frame: up to 18 months

07

Study locations

2 of 2 sites recruiting
  • Jiangsu Provincial People's Hospital
    Nanjing, Jiangsu 210029, China
    Recruiting
  • Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College
    Tianjin, Tianjin 300041, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Dec 2022, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Jul 23, 2021
StartActual
Feb 18, 2022
Primary completionEst.
Dec 2022
CompletionEst.
Aug 2024
Last update
Mar 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04975204
Responsible party
Sponsor
First posted
Jul 23, 2021
Start date
Feb 18, 2022
Primary completion
Dec 2022 (estimated)
Completion
Aug 2024 (estimated)
Last update
Mar 7, 2022

Study contacts

Jianyong Li, Doctor
Contact
lijianyonglm@126.com
13951877733
Wei Xu, Doctor
Contact
xuwei0484@jsph.org.cn
13951699449

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bcl-2 Inhibitor TQB3909

Start the discussion